Drug-Designation Biopharma (1,910 companies)
194 Companies
Access all companiesSpotfolio tracks over one million companies in technology industries.
There are 194 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Patients, Treatment, Therapeutics, Therapies, FDA, Phase, Drug-Designation .
Start-ups (17)
Early-stage companies (41)
Established companies (126)
The majority of these companies is located in the following countries.
United States (118)
Australia (7)
France (7)
United Kingdom (7)
Example Companies
Find companies in your areaBexion Pharmaceuticals
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
- Media & Press - Contact Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme ...
Multiforme from FDA Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme ...
Food and Drug Administration (FDA) has granted the company Orphan Drug designation for Saposin C, active ingredient in its proprietary drug BXQ-350 for ...
designation have become sought after assets.” About Orphan Drug Designation Orphan Drug designation is a status assigned to a medicine intended for use in ...
in rare diseases. In the U.S., the Orphan Drug Designation program confers Orphan Drug status to successful applicants for medicines intended for the safe ...
be speedier for Orphan Drugs than those which do not receive Orphan Drug designation. About BXQ-350 In pre-clinical studies, Bexion’s first-in-class biologic
Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant ...
Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma ...
of Orphan Drug Products Development reviews applications for Orphan Drug Designation to support development of medicines for underserved patient populations ...
and a potentially faster regulatory process. “Receiving this orphan drug designation for BXQ-350 is another important milestone emerging from our innovative
Zytoprotec
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Research FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid - Dialysis solution to improve outcomes of peritoneal dialysis - Phase ...
United States Food and Drug Administration (FDA) has granted orphan drug designation to PDprotec®, the Company's peritoneal dialysis fluid for the treatment ...
from end-stage renal disease in Europe and the United States. Orphan drug designation is a special status granted by the FDA to treatments for rare diseases
endpoints were successfully met. > read more Research FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid Vienna, Europe, December 14, ...
United States Food and Drug Administration (FDA) has granted orphan drug designation to PDprotec®, the Company's peritoneal dialysis fluid for the treatment
Aerial BioPharma Aerial BioPharma, LLC
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Biopharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development Aerial Biopharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in ...
molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development. The U.S. Food and Drug Administration
commercialize products that... Read More Aerial Biopharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development News Follows Successful Phase IIa ...
molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development. The U.S. Food and Drug Administration
REGiMMUNE Corporation
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
English RGI-2001 was granted Orphan Drug Designation from FDA Previous Next RGI-2001 was granted Orphan Drug Designation from FDA RGI-2001 has been granted ...
granted Orphan Drug Designation for RGI-2001 from FDA Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal ...
liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host ...
(GvHD) associated with hematopoietic stem cell transplantation. Orphan Drug Designation is a special status granted by FDA to a novel product to treat a rare
English RGI-2001 was granted Orphan Drug Designation from FDA Previous Next RGI-2001 was granted Orphan Drug Designation from FDA Tokyo, Japan-(OCT. 28 ...
company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host ...
(GvHD) associated with hematopoietic stem cell transplantation. Orphan Drug Designation is a special status granted by FDA to a novel product to treat a rare
Midatech Pharma
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Food and Drug Administration ("FDA") has granted the Company orphan drug designation for MTX110 for the treatment of patients with Malignant Glioma, including ...
adults. Commenting Craig Cook, CEO of Midatech said: "Receiving orphan drug designation for MTX110 is another important milestone to emerge from our innovative
Topics
Search by any topicOnly spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.
Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.
- 1B-Study
- 1B-Trial
- 2A-Study
- Accompanying-Prospectus
- Advanced-Solid-Tumors
- Breakthrough-Therapy-Designation
- Dose-Escalation-Study
- Dose-Level
- Escalation-Study
- Grants-Orphan
- Investigational-Medicine
- Investigational-Therapies
- Jefferies-Virtual
- Nasdaq-Listing
- Orphan-Drug-Status
- Orphan-Indication
- Patient-Dosed
- Phase-1B-Study
- Received-Orphan
- Received-Orphan-Drug
- Receives-Orphan
- Registrational
- TEAEs
- Therapy-Designation
- Treatment-Emergent
The following topics addressed by the majority of companies help you discover major players in the field.
- Biopharmaceutical-Company
- Biopharmaceutical-Company-Focused
- Clinical-Stage
- Drug-Designation
- FDA-Orphan
- FDA-Orphan-Drug
- Fast-Track-Designation
- Gemcitabine
- Global-Healthcare-Conference
- Granted-Orphan
- Granted-Orphan-Drug
- Oncology
- Ongoing-Phase
- Orphan-Designation
- Orphan-Drug
- Orphan-Drug-Designation
- Pediatric-Disease
- Phase-1B
- Phase-II-Study
- Pivotal-Phase
- Priority-Review
- Product-Candidates
- Rare-Pediatric
- Rare-Pediatric-Disease
- Track-Designation
All companies in this field address the following more general topics.
- Biopharmaceutical
- Biotechnology
- Board
- Cell
- Chief
- Clinical
- Clinical-Development
- Clinical-Trials
- Company
- Development
- Director
- Disease
- Dose
- Dr
- Drug
- Efficacy
- FDA
- Forward-Looking
- Forward-Looking-Statements
- Looking-Statements
- Medical
- Medicine
- Novel
- Orphan
- Patients
- Pharmaceutical
- Phase
- Pipeline
- Preclinical
- Research
- Scientific
- Study
- Therapeutics
- Therapies
- Treatment
- Trial
- University
Use Cases
Register nowTechnology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.
Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.